NASDAQ:HSCS Heart Test Laboratories (HSCS) Stock Price, News & Analysis $3.78 -0.16 (-4.06%) As of 06/4/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Heart Test Laboratories Stock (NASDAQ:HSCS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HSCS alerts:Sign Up Key Stats Today's Range$3.55▼$4.2950-Day Range$2.73▼$4.4952-Week Range$2.36▼$5.90Volume384,444 shsAverage Volume121,493 shsMarket Capitalization$4.09 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company OverviewHeart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.Read More… Heart Test Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreHSCS MarketRank™: Heart Test Laboratories scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHeart Test Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHeart Test Laboratories has only been the subject of 1 research reports in the past 90 days.Read more about Heart Test Laboratories' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Heart Test Laboratories are expected to grow in the coming year, from ($10.01) to ($8.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heart Test Laboratories is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heart Test Laboratories is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeart Test Laboratories has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Heart Test Laboratories' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.97% of the float of Heart Test Laboratories has been sold short.Short Interest Ratio / Days to CoverHeart Test Laboratories has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Heart Test Laboratories has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeart Test Laboratories does not currently pay a dividend.Dividend GrowthHeart Test Laboratories does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.97% of the float of Heart Test Laboratories has been sold short.Short Interest Ratio / Days to CoverHeart Test Laboratories has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Heart Test Laboratories has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Heart Test Laboratories this week, compared to 0 articles on an average week.Search Interest1 people have searched for HSCS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Heart Test Laboratories to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Heart Test Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Heart Test Laboratories is held by insiders.Percentage Held by InstitutionsOnly 17.24% of the stock of Heart Test Laboratories is held by institutions.Read more about Heart Test Laboratories' insider trading history. Receive HSCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heart Test Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address HSCS Stock News HeadlinesHeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic StenosisJune 4 at 9:00 AM | globenewswire.comFoundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP ValueJune 3 at 9:00 AM | globenewswire.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.June 5, 2025 | Porter & Company (Ad)HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial MilestoneMay 29, 2025 | globenewswire.comHeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025May 20, 2025 | globenewswire.comHeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew SimpsonMay 8, 2025 | globenewswire.comHeartSciences Adds Prominent Key Advisors to its Scientific Advisory BoardMay 7, 2025 | globenewswire.comHeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter ProgramMay 1, 2025 | globenewswire.comSee More Headlines HSCS Stock Analysis - Frequently Asked Questions How have HSCS shares performed this year? Heart Test Laboratories' stock was trading at $3.82 at the beginning of the year. Since then, HSCS shares have decreased by 1.0% and is now trading at $3.78. View the best growth stocks for 2025 here. How were Heart Test Laboratories' earnings last quarter? Heart Test Laboratories, Inc. (NASDAQ:HSCS) issued its quarterly earnings data on Thursday, March, 13th. The company reported ($2.57) earnings per share for the quarter, missing analysts' consensus estimates of ($2.53) by $0.04. When did Heart Test Laboratories' stock split? Heart Test Laboratories's stock reverse split on Friday, May 17th 2024. The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Heart Test Laboratories IPO? Heart Test Laboratories (HSCS) raised $9 million in an IPO on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company acted as the underwriter for the IPO. Who are Heart Test Laboratories' major shareholders? Heart Test Laboratories' top institutional investors include Astoria Strategic Wealth Inc. (1.75%). How do I buy shares of Heart Test Laboratories? Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heart Test Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heart Test Laboratories investors own include Meta Platforms (META), Cardio Diagnostics (CDIO), Invesco QQQ (QQQ), RH (RH), Exxon Mobil (XOM), Amarin (AMRN) and American Express (AXP). Company Calendar Last Earnings3/13/2025Today6/05/2025Next Earnings (Estimated)8/04/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:HSCS CIK1468492 Webheartsciences.com Phone682-237-7781FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$14.00 Low Stock Price Target$12.00 Potential Upside/Downside+243.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($7.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.61 million Net MarginsN/A Pretax Margin-50,833.34% Return on Equity-117.76% Return on Assets-84.09% Debt Debt-to-Equity Ratio0.01 Current Ratio1.72 Quick Ratio1.52 Sales & Book Value Annual Sales$14,700.00 Price / Sales277.97 Cash FlowN/A Price / Cash FlowN/A Book Value$11.16 per share Price / Book0.34Miscellaneous Outstanding Shares1,081,000Free Float962,000Market Cap$4.09 million OptionableNot Optionable Beta2.61 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:HSCS) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heart Test Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heart Test Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.